Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Carcinoma, Squamous Cell: early-phase trial registry
6 of 15 indexed Carcinoma, Squamous Cell trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 6 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Carcinoma, Squamous Cell: 15 US clinical trials tracked, 6 recruiting.
Carcinoma, Squamous Cell is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is UNC Lineberger Comprehensive Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition carcinoma-squamous-cell
OPEN 6 | RECR 40% | LATE 3 | EARLY 10 | RANK #1140 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)
Carcinoma, Squamous Cell lists 6 open slots (40% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Carcinoma, Squamous Cell on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Carcinoma, Squamous Cell is recruiting below its size-band peers.
6 of 15 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Carcinoma, Squamous Cell research.
UNC Lineberger Comprehensive Cancer Center accounts for 4 of 15 trials (26.7%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Carcinoma, Squamous Cell trials plan to enrol fewer than 100 people.
Median target enrolment is 53 among the 15 trials that report a genuine target (sentinel values excluded). 9 of those (60%) plan for fewer than 100 participants.
-
Carcinoma, Squamous Cell research is mostly interventional.
13 interventional and 2 observational studies make up this index (86.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Bicara Therapeutics
NCT04429542
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
UNC Lineberger Comprehensive Cancer Center
NCT04564989
Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
NCT04099290
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
University of Chicago
NCT06912087
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
University of Chicago
NCT06669572
Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC
Melissa Pugliano-Mauro
NCT03370406
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
Susanne Arnold
NCT02994069
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
Merck Sharp & Dohme
NCT06295809
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
NCT03174275
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
Providence Health & Services
NCT03336606
Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer
US Department of Veterans Affairs
NCT00007631
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
VA Office of Research and Development
NCT00847912
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
Merck Sharp & Dohme
NCT03833167
P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
UNC Lineberger Comprehensive Cancer Center
NCT03077243
A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer
State University of New York - Upstate Medical University
NCT00660218
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 5 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Carcinoma, Squamous Cell records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Carcinoma, Squamous Cell trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Carcinoma, Squamous Cell page
15 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Carcinoma, Squamous Cell trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- UNC Lineberger Comprehensive Cancer Center sponsors the most Carcinoma, Squamous Cell trials on record, review their full trial history before evaluating a specific study. See UNC Lineberger Comprehensive Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Carcinoma, Squamous Cell condition card totals 15 registered trials; most-linked intervention Pembrolizumab; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.